Last reviewed · How we verify
Placebo Oral tablet to match Venetoclax
Placebo Oral tablet to match Venetoclax is a Small molecule drug developed by Pharmacyclics LLC.. It is currently in Phase 3 development for Control arm in phase 3 clinical trials of venetoclax.
This is a placebo tablet formulated to match the appearance and administration of venetoclax in clinical trials.
This is a placebo tablet formulated to match the appearance and administration of venetoclax in clinical trials. Used for Control arm in phase 3 clinical trials of venetoclax.
At a glance
| Generic name | Placebo Oral tablet to match Venetoclax |
|---|---|
| Sponsor | Pharmacyclics LLC. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo control, this tablet contains no active pharmaceutical ingredient and serves as a comparator in phase 3 trials to assess the efficacy and safety of venetoclax. It is designed to be indistinguishable from the active venetoclax tablet to maintain blinding in randomized controlled studies.
Approved indications
- Control arm in phase 3 clinical trials of venetoclax
Common side effects
Key clinical trials
- Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) (PHASE2)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 (PHASE3)
- A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy (PHASE3)
- A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy (PHASE3)
- Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL) (PHASE3)
- Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia (PHASE3)
- Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Oral tablet to match Venetoclax CI brief — competitive landscape report
- Placebo Oral tablet to match Venetoclax updates RSS · CI watch RSS
- Pharmacyclics LLC. portfolio CI